Matthew Marano, MD
Ophthalmology · Livingston, NJNPI 1639112097
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 60.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $8,823 and has fallen 64.6% since, to $3,125 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 753 payments — averaging $52.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Sight Sciences, Inc.$5K
- Alcon$3K
- Bausch & Lomb Americas Inc.$2K
- Glaukos Corporation$987
- Sun Pharmaceutical Industries Inc.$593
- plus $4K from 22 others
What the payments were for
- Consulting fees$2,0005%
- Speaking & faculty fees$18,03646%
- Food & beverage$19,13549%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 218 | $23,563 |
| Sight Sciences, Inc. | 107 | $5,230 |
| Alcon | 86 | $3,256 |
| Bausch & Lomb Americas Inc. | 107 | $1,806 |
| Glaukos Corporation | 11 | $987 |
| Sun Pharmaceutical Industries Inc. | 28 | $593 |
| Amgen(2 entities) | 9 | $579 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $427 |
| Novartis | 51 | $419 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 45 | $394 |
| Ocular Therapeutix, Inc. | 18 | $268 |
| Oyster Point Pharma, Inc. | 13 | $226 |
| Harrow Eye, LLC | 7 | $221 |
| Biotissue Holdings Inc. | 11 | $204 |
| Mallinckrodt Hospital Products Inc. | 4 | $178 |
| Rxsight Inc | 1 | $147 |
| Iridex Corporation | 1 | $133 |
| Aerie Pharmaceuticals, Inc. | 8 | $114 |
| Kala Pharmaceuticals, Inc. | 6 | $107 |
| Tarsus Pharmaceuticals, Inc. | 5 | $94 |
| Carl Zeiss Meditec, Inc. | 1 | $67 |
| Omeros Corporation | 2 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| Shire North American Group Inc | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$18,544
- COMBIGAN$10,546
- OMNI(R) SURGICAL SYSTEM (US)$2,732
- ALPHAGAN P$2,375
- DURYSTA$2,114
- OMNI$973
- Clareon$631
- enVista MX60 IOL$588
- TEPEZZA$485
- SION SURGICAL INSTRUMENT$422
- AcrySof IQ VIVITY IOL$280
- KXL System$277
- Tecnis IOL$264
- iDose$240
- AcrySof IQ PanOptix UV IOL$236
- Hydrus Microstent$223
- ORA$150
- RXSIGHT CONTACT LENS$147
- RXSIGHT INJECTOR CARTRIDGE$147
- RXSIGHT INJECTOR HANDPIECE$147
How this compares
$39,191 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 165 | $217,147 |
| RestasisCyclosporine | 160 | $195,891 |
| LumiganBimatoprost | 355 | $168,689 |
| Cyclosporine | 106 | $73,576 |
| CombiganBrimonidine Tartrate/Timolol | 123 | $55,909 |
| Lotemax SmLoteprednol Etabonate | 190 | $49,165 |
| BesivanceBesifloxacin Hcl | 189 | $41,854 |
| ProlensaBromfenac Sodium | 102 | $36,751 |
| Alphagan PBrimonidine Tartrate | 82 | $33,450 |
| MieboPerfluorohexyloctane/Pf | 27 | $32,921 |
| VyzultaLatanoprostene Bunod | 46 | $27,281 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 151 | $23,479 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $22,865 |
| Bromfenac Sodium | 99 | $22,367 |
| CequaCyclosporine | 16 | $20,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $23,563 | $453,939720 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,806 | $277,350238 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Besivance, Prolensa, Loteprednol Etabonate | $394 | $133,066512 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $114 | $28,29243 claims |
| AlconSimbrinza | $3,256 | $22,86568 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $593 | $20,68116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Livingston
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.